Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Changhai Hospital
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed upper tract urothelial carcinoma (UTUC). For mixed histology, urothelial carcinoma must be the predominant component (≥50%).
Clinically non-metastatic disease (cN≤1, M0) as determined by cross-sectional imaging (CT or MRI of chest/abdomen/pelvis).
Planned treatment with radical nephroureterectomy (RNU).
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate renal function, defined as glomerular filtration rate (GFR) ≥ 45 mL/min, making the patient a potential candidate for cisplatin-based neoadjuvant chemotherapy.
Adequate organ and bone marrow function as determined by standard screening tests.
Recovery from all reversible toxicities of any prior surgery.
Age ≥ 18 years at the time of enrollment.
Ability to understand the study and provide signed informed consent.
You may not be if
Radiographic evidence of ≥cN2 lymph node disease or distant metastases (M1).
History of invasive, lymph node-positive, or metastatic urothelial carcinoma within 2 years prior to enrollment, or history of invasive contralateral UTUC.
Presence of only a solitary kidney or cisplatin ineligibility.
Concurrent participation in another interventional clinical trial at the time of enrollment.
History of a non-urothelial malignant tumor unless the patient has been disease-free for at least 1 year (exceptions include adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix).
Pregnancy or lactation. Women and men of reproductive potential must agree to use effective contraception.
Any other medical condition, comorbidity, or psychiatric illness that, in the investigator's judgment, would make the patient an unsuitable candidate for the study.
